Stifel analyst Paul Matteis raised the firm’s price target on Ionis Pharmaceuticals to $53 from $50 and keeps a Hold rating on the shares. While there are still a few key HELIOS-B questions that are yet to be answered, this result is bullish for Ionis’s eplontersen, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals announces FDA acceptance of olezarsen NDA
- Ionis Pharma expands donidalorsen licensing agreement in Asia Pacific
- Ionis Pharmaceuticals upgraded to Market Perform from Underperform at Bernstein
- JPMorgan biotech analysts hold an analyst/industry conference call
- Ionis reports ‘positive’ results from Phase 3 OASIS-HAE, OASISplus studies
Questions or Comments about the article? Write to editor@tipranks.com